Refractory thrombotic thrombocytopenic purpura and membranoproliferative glomerulonephritis successfully treated with rituximab: a case associated with hepatitis C virus infection.

Renal Unit, Department of Medicine and Geriatrics, Kwong Wah Hospital, Kowloon, Hong Kong.
Hong Kong medical journal = Xianggang yi xue za zhi / Hong Kong Academy of Medicine 07/2009; 15(3):201-8.
Source: PubMed

ABSTRACT Plasmapheresis remains the main treatment modality for patients with thrombotic thrombocytopenic purpura. We report a patient who had simultaneous onset of membranoproliferative glomerulonephritis and thrombotic thrombocytopenic purpura. She did not improve after 48 plasmapheresis sessions. A 6-week course of weekly intravenous doses of rituximab was then given. This achieved complete remission of her nephrotic syndrome and improvement in her renal function, so plasmapheresis was ceased. She had a low ADAMTS13 antigen level and a positive ADAMTS13 antibody, both of which reverted to normal after treatment with rituximab. This coincided with a rise in her hepatitis C virus RNA and liver transaminases. Liver biopsies did not reveal active fibrosis. Her hepatitis C virus RNA titre dropped afterwards, and she had no relapses of her thrombotic thrombocytopenic purpura and nephrotic syndrome, for more than 2 years after remission. The simultaneous onset and successful outcomes of both the membranoproliferative glomerulonephritis and thrombotic thrombocytopenic purpura illustrate the usefulness of rituximab. We discuss its use and risks, in the context of chronic hepatitis C infection.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Routing algorithms are required to guarantee the various quality of service (QoS) characteristics requested by the wide range of applications supported by broadband integrated services digital networks (B-ISDN). However, it is known that such a routing problem, with two or more additive or multiplicative QoS metrics in any possible combination is NP-complete. We propose a heuristic approach based on fuzzy logic. For each metric, a fuzzy membership function is defined to reflect the QoS requirements from that metric. A fuzzy-inference rule base is implemented to generate the fuzzy cost of each path based on the crisp values of the different metrics possibly used in the network links. The proposed approach is tested with different loads and the effect on different measures of performance is analyzed. Simulation results demonstrate the capability of this approach to increase the throughput and utilization of the communication network, and provide a fair distribution of different connection requests
    Communications, 1999. ICC '99. 1999 IEEE International Conference on; 02/1999
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background: Rituximab has increasingly been used for the treatment of hematological malignancies and autoimmune diseases, and its efficacy and safety are well established. Although clinical trials have shown conflicting results regarding the association of rituximab with infections, an increased incidence of infections has recently been reported in patients with lymphomas being treated with rituximab. However, clinical experience regarding the association of rituximab with different types of infection is lacking and this association has not been established in patients with rheumatoid arthritis.
    International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 11/2010; 15(1):e2-16. DOI:10.1016/j.ijid.2010.03.025 · 2.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Idiopathic thrombotic thrombocytopenic purpura (TTP) occurs primarily due to the formation of autoantibody against ADAMTS13, a specific von Willebrand factor-cleaving protease, resulting in low ADAMTS13 activity and subsequent accumulation of large vWF multimers, platelet aggregation and thrombus formation in the microvasculature of tissues. Limited clinical data suggest that the administration of anti-CD20 antibody (rituximab) may be useful in treating acute refractory or chronic relapsing idiopathic TTP. We carried out a systematic review with pooled data analysis using individual patient data to evaluate the efficacy of rituximab in these settings. Fifteen case series and 16 case reports comprising 100 patients were eligible for the study. Median age was 39 years. Male constituted 31 % and female 69 %. Complete remission was seen in 98 %, non-response in 2 % and relapse after complete remission in 9 %. For patients with complete remission, median follow-up was 13 months. Median platelet recovery from the first dose of rituximab was 14 days. ADAMTS13 inhibitor positivity and severe ADAMTS13 deficiency were highly predictive of the response to rituximab, implying that these can be useful markers in predicting response to rituximab in acute refractory or chronic relapsing idiopathic TTP.
    Journal of Thrombosis and Thrombolysis 05/2012; 34(3):347-59. DOI:10.1007/s11239-012-0723-9 · 2.04 Impact Factor


1 Download
Available from